- Home
- PANW vs REGN Comparison
PANW vs REGN Comparison
Compare PANW & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PANW | REGN |
|---|---|---|
| Founded | 2005 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 270.4B | 68.8B |
| IPO Year | 2012 | 1995 |
Fundamental Metrics
Financial Performance| Metric | PANW | REGN |
|---|---|---|
| Price | $377.80 | $777.20 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 39 | 25 |
| Target Price | $216.28 | ★ $830.16 |
| AVG Volume (30 Days) | ★ 5.8M | 529.5K |
| Earning Date | 05-19-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 0.55% |
| EPS Growth | N/A | ★ 8.19 |
| EPS | 0.40 | ★ 18.95 |
| Revenue | $2,273,100,000.00 | ★ $5,872,227,000.00 |
| Revenue This Year | $24.93 | $12.45 |
| Revenue Next Year | $19.97 | $10.13 |
| P/E Ratio | $937.73 | ★ $40.85 |
| Revenue Growth | ★ 29.04 | 20.82 |
| 52 Week Low | $139.57 | $541.00 |
| 52 Week High | $398.88 | $859.34 |
Technical Indicators
Market Signals| Indicator | PANW | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 57.94 | 44.16 |
| Support Level | $314.96 | $732.04 |
| Resistance Level | $398.88 | $782.44 |
| Average True Range (ATR) | 18.18 | 19.05 |
| MACD | 0.97 | -9.90 |
| Stochastic Oscillator | 81.43 | 5.05 |
Price Performance
Historical ComparisonAbout PANW Palo Alto Networks Inc.
Palo Alto Networks is a platform-based cybersecurity vendor with product offerings covering network security, cloud security, and security operations. The California-based firm has more than 80,000 enterprise customers across the world, including more than three-fourths of the Global 2000.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.